Enjoy complimentary customisation on priority with our Enterprise License!
About hyperphosphatemia
Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
PART 05: Introduction
Key market highlights
PART 06: Disease Overview
Understanding the disease
Etiology
Effects of hyperphosphatemia
Causes
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 07: Key developments in hyperphosphatemia therapy
PART 08: Guidelines for use of phosphate binders
CKD stages 2-4
CKD stage 5
PART 09: Pipeline analysis
Information on Pipeline Candidates
PART 10: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 11: Hyperphosphatemia management market dynamics
PART 12: Market segmentation by dosage form
Solid
Liquid
PART 13: Market segmentation by formulation
Aluminum-based phosphate binders
Calcium-based phosphate binders
Aluminum-free, calcium-free phosphate binder
Magnesium-based phosphate binders
Iron-based phosphate binders
PART 14: Geographical segmentation
Global hyperphosphatemia drugs market by Geography 2014-2019
Hyperphosphatemia drugs market in the Americas
Hyperphosphatemia drugs market in EMEA
Hyperphosphatemia drugs market in APAC
PART 15: Key leading countries
Hyperphosphatemia drugs market in the US
Hyperphosphatemia drugs market in Japan
PART 16: Market drivers
PART 17: Impact of drivers
PART 18: Market challenges
PART 19: Impact of drivers and challenges
PART 20: Market trends
PART 21: Vendor landscape
Competitive Scenario
Market Share Analysis 2014
Brand differentiation
Other prominent vendors
PART 22: Key vendor analysis
Fresenius Medical Care
Keryx Biopharmaceuticals, Inc.
Sanofi SA
Shire
Vifor Pharma
PART 23: Appendix
List of abbreviation
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.